Appendiceal neoplasms are exceedingly rare and represent approximately 1% of all diagnosed colorectal cancers (CRCs) each year in the United States, with an age-adjusted incidence of 0.12 cases per 1,000,000 people per year.1,2 This heterogeneous group of malignancies includes carcinoid tumors, mucinous adenocarcinomas, colonic (or intestinal) adenocarcinomas, and goblet cell tumors (adenocarcinoids). In a large series of appendiceal tumors derived from the SEER database between 1973 and 1998, the most frequent histology was mucinous adenocarcinoma, constituting approximately one-third of all cancers of the appendix.3
As with other malignancies, the extent of disease at time of diagnosis is the most important predictor of survival and correlates with the likelihood of surgical resection and potential cure. Among adenocarcinomas of the appendix the classic low-grade mucinous adenocarcinomas have superior survival compared with nonmucinous adenocarcinomas. Whether this improved outcome is related primarily to underlying biology or aggressive cytoreduction with or without hyperthermic intraperitoneal chemotherapy is still debated.
The role of modern systemic chemotherapy and targeted therapy in early or advanced nonmucinous and mucinous appendiceal adenocarcinomas (when surgery is not a viable option) has not been established. Several retrospective analyses4-6 failed to show a significant benefit from systemic chemotherapy. However, these were small series that did not distinguish tumor histology and were mostly performed in the era of single-agent 5-fluorouracil (5-FU). More recent case series have included patients receiving combination chemotherapy, and suggested response rates and outcomes more in line with those reported in advanced CRC.7-9
Given the rarity of appendiceal cancer, medical oncologists typically use combinations of agents similar to those used to treat metastatic CRC. The current study used the NCCN Oncology Outcomes Database (Outcomes Database) for CRC (2005-2012) to describe the systemic treatment patterns used for this rare group of tumors. Specifically, the study objectives were to identify and analyze the clinical efficacy of chemotherapy regimens used at NCCN Member Institutions to treat advanced appendiceal adenocarcinoma. The study also investigated the relationship between clinicopathologic features and outcome.
Connor S, Hanna G, Frizelle F. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum 1998;41:75–80.
McCusker M, Cote T, Clegg L, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the Surveillance, Epidemiology, and End-Results program 1973-1998. Cancer 2002;94:3307–3312.
Smith J, Kemeny N, Caldwell C et al.. Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1992;70:396–401.
Gough D, Donohue J, Schutt A et al.. Pseudomyxoma peritonei: Long-term patient survival with an aggressive regional approach. Ann Surg 1994;219:112–119.
Baratti D, Kusamura S, Nonaka D et al.. Pseudomyxoma peritonei: clinical, pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2008;15:526–534.
Shapiro J, Chase J, Wolff R et al.. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin. Cancer 2010;116:316–322.
Lieu CH, Lambert LA, Wolff RA et al.. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol 2012;23:652–658.
Farquharson AL, Pranesh N, Witham G et al.. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer 2008;99:591–596.
Song X, Zhao Z, Barber B et al.. Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics. Curr Med Res Opin 2011;27:123–130.
Love N, Haller DG. Patterns of care in medical oncology: management of cancer of the colon and rectum in the adjuvant and metastatic settings. Available at www.researchtopractice.com. 2008;5:1.
Benson AB III, Venook AP, Bekaii-Saab T et al.. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 3, 2014. Available at: NCCN.org. Accessed June 13, 2014.
Saltz LB, Clarke S, Diaz-Rubio E et al.. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013–2019.
Nitecki SS, Wolff BG, Schlinkert R et al.. The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg 1994;219:51–60.
Kabbani W, Houlihan PS, Luthra R et al.. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathologic features but similar genetic alterations. Mod Pathol 2002;15:599.
Sugarbaker P, Zhu B, Sese G et al.. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 1993;36:233.
Sugarbaker P, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727–731.
Sanoff HK, Carpenter WR, Martin CF et al.. Comparative effectiveness of oxaliplatin vs. non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 2012;104:211–227.
LaCasce AS, Vandergrift JL, Rodriguez MA et al.. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012;119:2093–2099.